Biocon Biologics Limited (BBL), a subsidiary of Indian biopharma company Biocon, has agreed to acquire the biosimilars business of Viatris, a US-based pharma company, in a deal worth up to $3.33 billion in a move to create a fully integrated global biosimilars enterprise. The consideration includes cash of up to $2.33 billion and $1 billion […]
Indian pharma company Biocon Limited has forged a partnership with Tabuk Pharmaceutical Manufacturing Company to commercialize certain specialty generic medicines in the Middle East. Tabuk Pharmaceutical is a wholly-owned subsidiary of Astra Industrial Group, a pharma company in the Middle East and North Africa (MENA) region. As per the agreement terms, Tabuk Pharmaceuticals will have […]
Biocon Ltd. said that its subsidiary — Biocon Biologics and Viatris have launched interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product in the US. The two products help regulate high blood sugar in adult as well as pediatric patients having type 1 diabetes and adults […]
Biocon has agreed to divest a stake of around 15% in its subsidiary — Biocon Biologics Limited (BBL) to Serum Institute Life Sciences Private Limited (SILS) at an enterprise value of around $4.9 billion. Serum Institute Life Sciences is a subsidiary of Serum Institute of India. The deal gives Biocon Biologics access to 100 million […]
Biocon Limited said that its subsidiary Biocon Biologics has been given an exclusive license from Adagio Therapeutics, a US-based biotech company, for manufacturing and commercializing an antibody treatment based on ADG20 for India and certain emerging markets. ADG20 is a novel monoclonal antibody that targets the spike protein of SARS-CoV-2 and related coronaviruses. It is […]
Biocon Ltd, an Indian biopharma company, has entered into a partnership with Brazilian pharma company Libbs Farmaceutica for launching generic drugs in Brazil. The company will be represented in the partnership by its fully-owned subsidiary Biocon Pharma. The partnership marks the foray of Biocon’s generic formulations into the Latin American region. It consolidates on the […]
Biocon, an Indian biopharma company, has expanded its generic formulations portfolio with the US launch of generic Tacrolimus capsules. Tacrolimus is a calcineurin inhibitor and an immunosuppressant, which was approved last month by the US Food and Drug Administration (FDA) for its use in the treatment of organ transplant patients. In organ transplant patients, the […]